Combined typhoid fever and hepatitis A vaccine: Comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years

Journal of Travel Medicine

Volumn 12, Issue 6, 2005, Pages 319-326

  Overbosch, David ^a   Peyron, François ^b   Picot, Nicole ^c   Varichon, Jean Paul ^d   Dumas, Rafaele ^e   Chambonneau, Laurent ^e   Weber, Françoise ^e  

^a Havenziekenhuis   (Netherlands)

^b CROIX ROUSSE HOSPITAL   (France)

^c CHU PURPAN   (France)

^d Clinique Jeanne d'Arc   (France)

^e SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; TYPHOID VACCINE; VIATIM;

ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; ASTHENIA; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; FEVER; HEADACHE; HEPATITIS A; HUMAN; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; SEROCONVERSION; SIDE EFFECT; SYSTEMIC DISEASE; TYPHOID FEVER; VACCINATION;

EID: 30944452364     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2005.12604     Document Type: Article

References (23)

1. Feinstone SM, Gust ID. Hepatitis A virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 5th Ed. New York: Churchill Livingstone, 2000:1920-1940.
2. Steffen R, Kane MA, Shapiro CN, et al. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994; 272:885-889.
3. Steffen R, DuPont HL. Manual of travel medicine and health. Hamilton, ON: BC Decker, 1999.
4. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998; 158:633-638.
5. Centers for Disease Control and Prevention. Typhoid immunization- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1994; 43(RR-14):1-7.
6. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45(RR-15):1-30.
7. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48(RR-12):1-37.
8. Musharrafieh UM, Bizri AR, Hajj IE. Health risks for travelers to Lebanon. J Travel Med 2003; 10:280-285.
9. Loebermann M, Kollaritsch H, Ziegler T, et al. A multicenter, randomized, double-blind, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. Clin Ther 2004; 26:1084-1091.
10. Beeching NJ, Clarke PD, Kitchin NRE, et al. Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine 2004; 23:29-35.
11. Beran J, Chlibek R, Weber F. A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. Vaccine 2003; 21:4650-4654.
12. Tacket CO, Ferreccio C, Robbins JB, et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis 1986; 154:342-345.
13. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15:657-680.
14. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17:873-890.
15. Van Hoecke C, Lebacq E, Beran J, et al. Concomitant vaccination against hepatitis A and typhoid fever. J Travel Med 1998; 5:116-120.
16. Beran J, Beutels M, Levie K, et al. A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. J Travel Med 2000; 7:246-252.
17. Bovier PA, Bock J, Loutan L, et al. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 2002; 68:489-493.
18. Bell BP. Hepatitis A vaccine. Pediatr Infect Dis J 2000; 19:1187-1188.
19. Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 2004; 72:194-196.
20. Klugmann KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate or protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after vaccination. Vaccine 1996; 14:435-438.
21. Plotkin SA, Bouvert le Cam N. A new typhoid vaccine of the Vi capsular polysaccharide. Arch Int Med 1995; 155:2293-2299.
22. Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 1999; 18:609-620.
23. Lebacq E. Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration. Biodrugs 2001; 15(Suppl 1):5-12.